Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
Authors:
Open Access
- 4 August 2022
- journal article
- research article
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 71 (3) , 249-254
Abstract
Mesalamine is a key drug in the treatment of ulcerative colitis (UC) for both induction and maintenance therapy. On the other hand, it is known that there are some cases of mesalamine intolerance that are difficult to distinguish from symptoms due to aggravation of UC. The aim of this study is to investigate the clinical characteristic of mesalamine intolerance in UC. A retrospective, observational study was conducted. We enrolled 31 patients who were diagnosed as mesalamine intolerance between April 2015 to March 2020. We examined clinical features, time to onset, drug types of mesalamine, DLST positive rate, colonoscopy findings, disease activity, and clinical course after diagnosis. The average dose of mesalamine was 3.69 g and DLST-positive was 57.1%. Within the first 2 weeks from the start of mesalamine, 51.6% showed symptoms of intolerance. The serum CRP level was relatively high at ≥10.0 mg/dl in 53.6% of the cases. There was no difference in clinical background, symptoms, or laboratory findings between patients with DLST-positive and negative. In this study, we clarified the clinical characteristics of mesalamine intolerant patients, and found no difference in the clinical background or success rate of desensitization therapy between positive and negative DLST cases.Keywords
This publication has 40 references indexed in Scilit:
- Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative ColitisCase Reports in Gastroenterology, 2011
- Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussionWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2010
- Recent status of drug‐induced liver injuryHepatology Research, 2008
- Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2000
- Mesalazine-associated interstitial nephritis: twice in the same patient.Nephrology Dialysis Transplantation, 1997
- The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificityClinical & Experimental Allergy, 1997
- Mesalazine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Chronic Inflammatory Bowel DiseaseDrugs, 1989
- Adverse Effects with Oral 5-Aminosalicyclic AcidJournal of Clinical Gastroenterology, 1988
- Sulfasalazine and Salicylate-Induced Exacerbation of Ulcerative ColitisNew England Journal of Medicine, 1987
- Salicylate induced exacerbation of ulcerative colitis.Gut, 1987